A Phase 2/3 interventional study of Corticosteroids (prednisone or prednisolone) and Abatacept in Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Terminated at 84 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-20.
Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Mycophenolic Acid in Lupus Erythematosus, Systemic — 4 open to participants now, 4 under way, none of them phase 3. Mycophenolic Acid · Lupus Erythematosus, Systemic.
Among the 14 studies testing Mycophenolic Acid in Lupus Erythematosus, Systemic, this one has the largest enrollment, is one of 2 that started in 2007, is the only one in phase 2/3, and was the 1st registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 14 studies testing Mycophenolic Acid in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 16–70 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–65
By country, each count listing its studies:
Mycophenolic Acid: first FDA approval 1995 (CELLCEPT), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 3 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 423 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 63 across the 14 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb: 5 open now, 9 under way, 3 of them phase 3. Of 11 finished, 7 (64%) have results posted.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2007, is the only one in phase 2/3, and was the 2nd registered.
Bristol-Myers Squibb’s Lupus Erythematosus, Systemic studies by the year they started, since 2005.
1 of the studies testing Mycophenolic Acid in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing Mycophenolic Acid in Lupus Erythematosus, Systemic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 20 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.
Double Blind Period: Treatment, Parallel Assignment, Double Blind (Subject, Investigator), Randomized, Active Control, Safety/Efficacy Study
Open Label Period: Prevention, Single Group Assignment, Open Label, Uncontrolled, Safety/Efficacy Study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short-term Period
Drug: Corticosteroids (prednisone or prednisolone) · Drug: Abatacept · Drug: Mycophenolate mofetil (MMF)
Short-term Period
Drug: Corticosteroids (prednisone or prednisolone) · Drug: Abatacept · Drug: Mycophenolate mofetil (MMF)
Short-term Period
Drug: Corticosteroids (prednisone or prednisolone) · Drug: Mycophenolate mofetil (MMF)
Long-term Extension Period
Drug: Abatacept
tablets, oral, 0.5-0.8 mg/kg, daily
intravenous solution, injectable, 30 mg/kg, every 28 days
Also known as: Orencia, BMS-188667
intravenous solution, injectable, 10 mg/kg, every 28 days
Also known as: Orencia, BMS-188667
tablets, oral, 1.5 to 2 g, daily
intravenous solution, injectable, 10 mg/kg, every 28 days
Time to First Confirmed Complete Renal Response (CRR) During the Short-term (Double-blind) Period
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
Time frame: Day 1 (randomization) to 12 months.
Number of Participants With Confirmed Complete Renal Response (CRR) During Short-term Period
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
Time frame: Day 1 to 12 months
Participants Achieving a Confirmed Complete Renal Response (CRR) at Month 12 During Short-term Period
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
Time frame: At Month 12 from Day 1
Time to Achieve First Confirmed Renal Improvement (RI) During Short-term Period (as Determined by Kaplan-Meier Methodology)
RI is defined as meeting all of the following criteria. Renal function: If MDRD is abnormal at screening, within 10% of the MDRD at screening; if MDRD is 60-89 at screening, greater than or equal to 50% improvement based on the screening value or 90% or greater of MDRD at screening; if MDRD is 15-59 at screening, if MDRD is normal at screening-within 10% of the MDRD at screening. Proteinuria: improvement greater than or equal to 50% from screening. Hematuria: red blood cell (RBC)count within normal limit of central laboratory. Pyuria: white blood cell (WBC) count within normal limit of central laboratory. Cylindruria: No RBC or WBC casts.
Time frame: Day 1 (randomization) to 12 months.
Participants Achieving Renal Improvement (RI) or CRR at Month 12 During Short-term Period
CRR defined as meeting all of 5 criteria. RF: (Glomerular filtration rate \[GFR\] calculated using MDRD equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
Time frame: At Month 12 from Day 1
Number of Months CRR Was Maintained During Short-term Period
Durability of CRR, defined as the number of months (number of consecutive planned visits beyond Day 15) a participant met the definition of CRR during the double-blind treatment period. Refer to outcome 1 for description of CRR.
Time frame: Day 1 (randomization) to 12 Months
Baseline Renal Function Over Time During Short-term Period
Baseline (BL) renal function, as estimated by calculation of the MDRD (Modification of Diet in Renal Disease) equation, over time. Renal MDRD is an equation (calculation) used to estimate Glomerular Filtration Rate (GFR) in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine. A negative value indicates worsening.
Time frame: Baseline (Day 1), Day 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365
Change in Renal Function From Baseline Over Time During Short-term Period
Mean change from baseline in renal function, as estimated by calculation of the MDRD equation, over time. Renal MDRD is an equation (calculation) used to estimate Glomerular Filtration Rate (GFR) in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine. A positive value indicates improvement. Change from baseline=Post-baseline-baseline value.
Time frame: Baseline (Day 1), Day 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365
Baseline and Post Baseline Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index During Short-term Period
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as nonreversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity.
Time frame: Baseline (Day 1), Post baseline (Month 12 or 28 days after last dose)
Number of Participants Achieving Renal Response (RR) at Month 12 During Short-term Period
RR is defined as meeting BOTH of the following criteria:RENAL FUNCTION: Less than or equal to 25% increase from baseline;PROTEINURIA: Greater than or equal to 50% improvement in the urine protein/creatinine ratio with one of the following - urine protein/creatinine ratio (UPCR) \<113 mg/mmol,, if the baseline ratio was \<=339 mg/mmol OR UPCR \<339 mg/mmol,if the baseline ratio \> 339 mg/mmol. A participant was considered as achieving RR if response criteria at both months 11 and 12 (Days 337 and 365, respectively) were met. For 95% CI within each group, normal approximation is used if n\>=5.
Time frame: Month 12
Change in SLICC/ACR Damage Index From Baseline During Short-term Period
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity. Change from baseline=Postbaseline - baseline value.
Time frame: Baseline (Day 1), Postbaseline (Month 12 or 28 days after last dose)
Baseline Physical Component Summary of the Short Form (SF)-36 During Short-term Period
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Change From Baseline in Physical Component Summary of the SF-36 During Short-term Period
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Baseline Mental Component Summary of the Short SF-36 During Short-term Period
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Change From Baseline in Mental Component Summary of the SF-36 During Short-term Period
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Baseline Fatigue as Measured by the Fatigue Visual Analog Scale During Short-term Period
A visual analogue scale (VAS) is a psychometric response scale for measurement of subjective characteristics or attitudes that cannot be directly measured. The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Change in Fatigue From Baseline as Measured by the Fatigue Visual Analog Scale During Short-term Period
A visual analogue scale is a psychometric response scale for measurement of subjective characteristics or attitudes that cannot be directly measured. The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Baseline Fatigue as Measured by Fatigue Severity Scale-Krupp During Short-term Period
The reduction of fatigue assessed by Fatigue Severity Scale (FSS). The FSS questionnaire is comprised of 9 statements inquiring about the examinee's sleep habits over the preceding week. Participants are asked to rate their level of agreement (toward seven) or disagreement (toward zero) with the nine statements. A score of 36 and above (out of a maximum of 63) indicates the presence of significant fatigue.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Change in Fatigue From Baseline as Measured by Fatigue Severity Scale-Krupp During Short-term Period
The reduction of fatigue assessed by Fatigue Severity Scale (FSS). The FSS questionnaire is comprised of 9 statements inquiring about the examinee's sleep habits over the preceding week. Participants are asked to rate their level of agreement (toward seven) or disagreement (toward zero) with the nine statements. A score of 36 and above (out of a maximum of 63) indicates the presence of significant fatigue.
Time frame: Baseline (Day 1), Days 85, 169, 253, and 365
Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs Reported During the Short-term Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=possibly, probably, or certainly related to and of unknown relationship to study drug.
Time frame: From Baseline (Day 1) up to 56 days post last dose in the double-blind period or the first dose in the open-label long-term extension, whichever occurred first.
Participants With AEs of Special Interest During the Short-term Period
AEs of special interest were prospectively identified to be those that may be associated with the use of immunomodulatory agents. They are a subset of all AEs and may be either serious or non-serious.
Time frame: From Baseline (Day 1) up to 56 days post last dose in the double-blind period or the first dose in the open-label long-term extension, whichever occurred first.
Participants With Marked Hematology Abnormalities During the Short-term Period
LLN=lower limit of normal; ULN=upper limit of normal; PTV=pretreatment value. Normal ranges are provided by the Central Laboratory and may vary according to sex and age. Low(↓)Hemoglobin:\>3g/dL decrease from PTV; ↓Hematocrit:\<0.75xPTV;↓Erythrocyte count:\<0.75xPTV; high(↑)Platelet count:\>1.5xULN;↓Platelet count:\<0.67xLLN;↓Leukocyte count:\<0.75X LLN;↑Leukocyte count:\>1.25xULN;↓Absolute(AB)Neutrophils+Bands:\<1.00x10\^3c/uL;↑AB Lymphocyte count:\>7.50x10\^3 c/uL; ↓AB lymphocyte count:\<0.750x10\^3 c/uL;↑AB monocyte count:\>2000/mm\^3;↑AB basophil count:\>400/mm\^3;↑AB eosinophil count:\>0.750x10\^3 c/uL.
Time frame: From Baseline (Day 1) up to 56 days post last dose in the double-blind period or the first dose in the open-label long-term extension, whichever occurred first.
Participants With Marked Laboratory Abnormalities During the Short-term Period
LLN=lower limit of normal; ULN=upper limit of normal; PTV=pretreatment value. Normal ranges are provided by the Central Laboratory and may vary according to sex and age. ↑Serum Sodium:\>1.05x ULN;↓Serum Potassium:\<0.9x LLN;↑Serum Potassium:\>1.1x ULN;↓Total Calcium:\<0.8X LLN;↑Total Calcium:\>1.2x ULN; ↓Serum Glucose(SG):\<65 mg/dL;↑SG:\>220 mg/dL;↓Fasting SG:\<0.8x LLN;↑Fasting SG:\>1.5x ULN;↓Total Protein:\<0.9x LLN;↓Albumin:\<0.9x LLN;↑Total Cholesterol:\>2x PTV;↑Triglycerides:\>=2.5x ULN;↑Fasting Triglycerides:\>=2x ULN
Time frame: From Baseline (Day 1) up to 56 days post last dose in the double-blind period or the first dose in the open-label long-term extension, whichever occurred first.
Participants With Marked Liver and Kidney Function Abnormalities During the Short-term Period
ULN=upper limit of normal; PTV=pretreatment value. Normal ranges are provided by the Central Laboratory and may vary according to sex and age. Alkaline Phosphatase:\>2x ULN; ↑Aspartate Aminotransferase: \>3x ULN; ↑Alanine Aminotransferase : \>3x ULN; G-Glutamyl Transferase : \>2x ULN; ↑Total Bilirubin : \>2x ULN or if PTV \> ULN then \> 4x PTV; ↑Blood Urea Nitrogen \>2x PTV; ↑Creatinine \>1.5x PTV.
Time frame: From Baseline (Day 1) up to 56 days post last dose in the double-blind period or the first dose in the open-label long-term extension, whichever occurred first.
Participants With Marked Abnormalities Urinalysis During the Short-term Period
PTV=pretreatment value. Criteria for marked abnormality: Protein, glucose, blood, leukocyte esterase , if missing PTV then use \>=2+ (or, if value \>=4, or if PTV=0 or 0.5, \>=2 or if PTV=1, \>=3, or if PTV=2 or 3, \>=4).
Time frame: From Baseline (Day 1) up to 56 days post last dose in the double-blind period or the first dose in the open-label long-term extension, whichever occurred first.
Vital Signs Summary During the Short-term Period: Systolic Blood Pressure (SBP)
Time frame: 0 - 12 Months
Vital Signs Summary During the Short-term Period: Diastolic Blood Pressure (DBP)
Time frame: 0 - 12 Months
Vital Signs Summary During the Short-term Period: Heart Rate
Time frame: 0 - 12 Months
Vital Signs Summary During the Short-term Period: Temperature
Time frame: 0 - 12 Months
Number of Participants With Positive Abatacept-induced Responses (ECL Method) Over Time During the Short-term Period
A validated, sensitive electrochemiluminescence (ECL) immunoassay based on Meso-Scale Discovery instrumentation was used to evaluate immunogenicity. The ECL assay differentiated between two antibody specificities: (1) the 'Ig and/or Junction (Jn) Region' and (2) 'CLTA4 and possibly Ig'. A sample was considered positive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept with or without CTLA4-T.
Time frame: Day 169, Day 365
Baseline Quantitative Immunoglobulins During the Short-term Period
A quantitative immunoglobulins (Igs) test is used to detect abnormal levels of the three major classes of Igs (IgG, IgA, and IgM). Abnormal test results typically indicate that there is something affecting the immune system which requires further testing.
Time frame: Baseline (Day 1)
Change in Quantitative Immunoglobulin From Baseline During Short-term Period
A quantitative immunoglobulin (Ig) test is used to detect abnormal levels of the 3 major classes of Ig (IgG, IgA, and IgM). Abnormal test results typically indicate that something is affecting the immune system and further testing is required. Please refer to Outcome 31 for the respective baseline values
Time frame: Day 365
Number of Participants Achieving Complete Response by ACCESS Definition
The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS) defines complete response as a response meeting all of the following criteria: serum creatinine ≤upper limit of normal as defined by the central laboratory or ≤125% of the higher value at either screening or baseline; urine protein/creatinine ratio \<50 mg/mmoL; and prednisone or prednisone-equivalent dose tapered to 10 mg per day.
Time frame: End of short-term period (Day 365) to termination of the long-term extension period
Number of Participants Achieving Patient Response of Complete or Partial Response, Based on the June 2010 Food and Drug Administration Guidance Document for Lupus Nephritis
Patient response=complete, partial, or no response. Complete response=serum creatinine (SCr) normal, inactive urinary sediment, no cellular casts, urinary protein/creatinine (UPCR) ratio\<56.5 mg/mmol. Partial response=SCr normal or ≤25% above baseline value, RBCs at reference range, UPCR \<56.5 mg/mmoL OR ≥50% improvement in UPCR with one of the following: UPCR \<113 or \<339 mg/mmoL, based on the baseline ratio. No response=Not achieving complete or partial response criteria.
Time frame: At Day 365 (end of Short-term Period) and Day 645
Mean Change From Baseline in SLICC/ACR Damage Index
SLICC=Systemic Lupus International Collaborating Clinics; ACR=American College of Rheumatology. The SLICC/ACR Damage Index measures organ damage (nonreversible change, unrelated to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months unless otherwise stated. The index assesses 47 items in 12 systems: Ocular, Neuropsychiatric, Renal, Pulmonary, Cardiovascular, Gastrointestinal, Peripheral Vascular, Musculoskeletal, Skin, Premature Gonadal Failure, Diabetes, Malignancy. Scores range from 0 to 2, and the same lesion cannot be scored twice. If damage is noted for a particular item, it is scored 1. No damage is scored 0. Some items may score 2 points if they occur more than once, so that the maximum possible score is 47. Scores can only increase with time, but scores rarely reach over 12. It is usually completed (or updated) yearly.
Time frame: Day 365 to termination of the long-term extension phase
Number of Participants With Death, Serious Adverse Events (SAE), Treatment-related Adverse Events SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs During Long-term Extension Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=possibly, probably, or certainly related to and of unknown relationship to study drug.
Time frame: From start of study drug in long-term period (Day 365) to up to 56 days after the last dose of the long-term extension (LTE). Deaths in LTE reported to >56 days post last dose.
Number of Participants With a Treatment-emergent Seropositive Result During the Long-term Extension Period
Collected in at least 1 sample. Assessment includes immunogenicity (detection of serum antibodies which bind to CTLA4-Ig in the in vitro assays) and exposure to corticosteroids
Time frame: Day 365 to end of long-term extension period
Number of Participants Achieving Renal Response
Renal response=serum creatinine level ≤25% above baseline value and greater than or equal to 50% improvement in the urine protein/creatinine ratio with 1 of the following: urine protein/creatinine ratio (UPCR) \<113 mg/mmol, if the baseline ratio was \<= 339 mg/mmol OR UPCR \<339 mg/mmol,if the baseline ratio \>339 mg/mmol.
Time frame: At Day 365 (end of short-term period) and Day 645
Number of Participants With Marked Laboratory Abnormalities During the Long-term Extension Period
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Hemoglobin (g/dL): \>3g/dL decrease from preRX value. Hematocrit(%): \<0.75\*preRX. Erythrocytes (\*10\^6 c/uL): \<0.75\*preRX. Platelet count (\*10\^9 c/L): \<0.67\*LLN, or \>1.5\*ULN, or if preRX \<LLN, use \<0.5\*preRX and \<100,000/mm\^3. Leukocytes (\*10\^3 c/uL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\* preRX or \>ULN; if preRX\>ULN, use \>1.2\*preRX or \<LLN. Neutrophils + Bands (absolute) (\*10\^3 c/uL): If value \<1.0\*10\^3 or if value \>7.50\*10\^3 c/uL. Monocytes (absolute) (\*10\^3 c/uL): If value \>2000/mm\^3. Basophils (absolute)(\*10\^3 c/uL): If value \>.750\*10\^3 c/uL. Eosinophils (absolute) (\*10\^3 c/uL): If value \>.750\*10\^3 c/uL. ALP (U/L): \>2\*ULN, or if preRX\>ULN, use \>3\* preRX. AST (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX. ALT (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX. GGT (U/L):\>2\*ULN, or if preRX \>ULN, use \>3\*preRX. Bilirubin, total (mg/dL): \>2\*ULN, or if preRX\>ULN, use \>4\*preRX. BUN (mg/dL): \>1.5\*preRX.
Time frame: From start of study drug on Day 365 up to 56 days after last dose in the long-term extension period
Number of Participants With Marked Laboratory Abnormalities During the Long-term Extension Period (Continued)
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium, serum (mEq/L): \<0.95\*LLN or \>1.05\*ULN, or if preRX\<LLN, use \<0.95\*preRX or \>ULN if preRX\>ULN, use \>1.05\*preRX or \<LLN. Potassium, serum (mEq/L): \<0.9\* LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN. Chloride, serum (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRX\<LLN, use \<0.9\*preRX or \>ULN. Calcium, total (mg/dL): \<0.8\*LLN or \>1.2\*ULN, or if preRX\<LLN, use \<0.75\*preRX or \>ULN if preRX\>ULN, use \>1.25\*preRX or \<LLN. Glucose, serum (mg/dL): \<65 mg/dL, or \>220 mg/dL. Glucose, fasting serum (mg/dL): \<0.8\*LLN or \>1.5\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN if preRX\>ULN, use \>2.0\*preRX or \<LLN. Albumin (g/dL): \<0.9\*LLN, or if preRX \<LLN, use \<0.75\*preRX. Cholesterol, total (mg/dL): \>2\*preRX. Triglycerides (mg/dL): \>=2.5\*ULN, or if preRX\>ULN, use \>=2.5\*preRX. Triglycerides, fasting (mg/dL): \>=2\*ULN, or if preRX\>ULN, use \>2.0\*preRX.
Time frame: From start of study drug on Day 365 up to 56 days after last dose in the long-term extension period
Number of Participants With Marked Laboratory Abnormalities During the Long-term Extension Period (Continued)
preRX=pretreatment. Protein, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX =0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 OR 3 then use \>=4. Glucose, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 or 3, use \>=4. Blood, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX =0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 or 3, use \>=4. Leukocyte esterase, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 or 3, use \>=4.
Time frame: From start of study drug on Day 365 to up to 56 days after last dose in the long-term extension period
Number of Participants Achieving Patient Response (PR) at Month 12 During the Short-term Period
PR is either CRR, Partial Renal Response(PRR),or no Response(NR). CRR= Serum creatinine(SC)is normal, Inactive urinary sediment, No cellular casts, Urinary protein/creatinine (UPCR) ratio \<56.5 mg/mmoL; PRR= SC is normal OR SC not \>25% above BL, RBCs at reference range, UPCR \<56.5 mg/mmoL OR ≥50% improvement in UPCR with one of the following: UPCR \<113 or \<339 mg/mmoL, based on the BL ratio; NR= Not achieving either a CRR or a PRR. Participants achieved response if criteria at both months 11 and 12 (Days 337 and 365) were met. Participants who Early discontinuations were categorized as NR.
Time frame: Month 12
| Milestone | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Started | 99 | 99 | 100 |
| Completed | 76 | 74 | 78 |
| Not completed | 23 | 25 | 22 |
| Withdrew: Death | 1 | 1 | 5 |
| Withdrew: Adverse event | 15 | 13 | 9 |
| Withdrew: Lack of efficacy | 5 | 6 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Withdrew: Participant no longer met study criteria | 1 | 1 | 2 |
| Withdrew: Poor compliance/ noncompliance | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 2 | 0 |
| Milestone | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Started | 70 | 67 | 74 |
| Completed | 10 | 9 | 11 |
| Not completed | 60 | 58 | 63 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Adverse event | 3 | 2 | 5 |
| Withdrew: Lack of efficacy | 5 | 3 | 8 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 5 | 1 | 2 |
| Withdrew: Pregnancy | 1 | 1 | 0 |
| Withdrew: Administrative reason by sponsor | 41 | 49 | 46 |
| Withdrew: Other | 2 | 1 | 1 |
| Withdrew: Poor compliance/noncompliance | 1 | 0 | 0 |
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
| days | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Time to First Confirmed Complete Renal Response (CRR) During the Short-term (Double-blind) Period | NA (NE to NE) | NA (NE to NE) | NA (NE to NE) |
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Number of Participants With Confirmed Complete Renal Response (CRR) During Short-term Period | 22 | 27 | 20 |
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Participants Achieving a Confirmed Complete Renal Response (CRR) at Month 12 During Short-term Period | 9 | 11 | 8 |
RI is defined as meeting all of the following criteria. Renal function: If MDRD is abnormal at screening, within 10% of the MDRD at screening; if MDRD is 60-89 at screening, greater than or equal to 50% improvement based on the screening value or 90% or greater of MDRD at screening; if MDRD is 15-59 at screening, if MDRD is normal at screening-within 10% of the MDRD at screening. Proteinuria: improvement greater than or equal to 50% from screening. Hematuria: red blood cell (RBC)count within normal limit of central laboratory. Pyuria: white blood cell (WBC) count within normal limit of central laboratory. Cylindruria: No RBC or WBC casts.
| Days | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Time to Achieve First Confirmed Renal Improvement (RI) During Short-term Period (as Determined by Kaplan-Meier Methodology) | 141 (88 to 169) | 136 (92 to 171) | 144 (113 to 198) |
CRR defined as meeting all of 5 criteria. RF: (Glomerular filtration rate \[GFR\] calculated using MDRD equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater of level at screening visit. Proteinuria: urinary protein/creatinine ratio \<30 mg/mmol. Hematuria: red blood cell (RBC) count within normal limits of Central Laboratory. Pyuria: White blood cell count (WBC) within normal limits of Central Laboratory. Cylindruria: No RBC or WBC casts reported.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Participants Achieving Renal Improvement (RI) or CRR at Month 12 During Short-term Period | 38 (28.8 to 48.0) | 37 (27.8 to 46.9) | 31 (21.9 to 40.1) |
Durability of CRR, defined as the number of months (number of consecutive planned visits beyond Day 15) a participant met the definition of CRR during the double-blind treatment period. Refer to outcome 1 for description of CRR.
| Months | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Number of Months CRR Was Maintained During Short-term Period | 0 ± 1.5 | 0 ± 1 | 0 ± 1.1 |
Baseline (BL) renal function, as estimated by calculation of the MDRD (Modification of Diet in Renal Disease) equation, over time. Renal MDRD is an equation (calculation) used to estimate Glomerular Filtration Rate (GFR) in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine. A negative value indicates worsening.
| milliliters per minute (mL/min)/1.73 m^2 | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Baseline (Day 1) for Day 15 (n=98,94,98) | 92.57 ± 36.57 | 99.09 ± 35.41 | 91.01 ± 29.60 |
| Baseline (Day 1) for Day 29 (n=98,95,98) | 93.08 ± 36.14 | 98.56 ± 36.26 | 91.23 ± 29.33 |
| Baseline (Day 1) for Day 57 (n=94, 89, 96) | 91.54 ± 35.99 | 98.76 ± 35.96 | 91.58 ± 28.93 |
| Baseline (Day 1) for Day 85 (n=90, 91, 93) | 94.53 ± 35.53 | 100.22 ± 35.50 | 92.76 ± 29.01 |
| Baseline (Day 1) for Day 113 (n=91, 83, 91) | 94.43 ± 35.80 | 101.23 ± 35.38 | 92.41 ± 28.15 |
| Baseline (Day 1) for Day 141 (n=89, 83, 90) | 93.62 ± 35.74 | 101.05 ± 35.73 | 92.83 ± 29.10 |
| Baseline (Day 1) for Day 169 (n=83, 82, 85) | 94.83 ± 36.10 | 101.95 ± 35.82 | 92.56 ± 29.85 |
| Baseline (Day 1) for Day 197 (n=84, 81, 87) | 94.55 ± 35.98 | 101.85 ± 36.26 | 92.69 ± 29.51 |
| Baseline (Day 1) for Day 225 (n=84, 81, 84) | 94.87 ± 35.82 | 101.64 ± 36.26 | 93.25 ± 29.75 |
| Baseline (Day 1) for Day 253 (n=81, 76, 81) | 94.89 ± 36.24 | 101.25 ± 36.67 | 93.38 ± 30.07 |
| Baseline (Day 1) for Day 281 (n=78, 77, 80) | 94.17 ± 36.55 | 102.64 ± 36.76 | 93.13 ± 30.13 |
| Baseline (Day 1) for Day 309 (n=77, 76, 78) | 94.74 ± 36.81 | 100.64 ± 33.80 | 92.71 ± 30.23 |
| Baseline (Day 1) for Day 337 (n=74, 75, 79) | 95.51 ± 37.30 | 101.00 ± 33.89 | 92.90 ± 30.13 |
| Baseline (Day 1) for Day 365 (n=75, 73, 78) | 95.04 ± 37.24 | 101.30 ± 34.21 | 93.03 ± 30.53 |
Mean change from baseline in renal function, as estimated by calculation of the MDRD equation, over time. Renal MDRD is an equation (calculation) used to estimate Glomerular Filtration Rate (GFR) in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine. A positive value indicates improvement. Change from baseline=Post-baseline-baseline value.
| milliliters per minute (mL/min)/1.73 m^2 | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 15; (n=98,94,98) | -0.24 ± 2.08 | 1.15 ± 2.11 | 0.62 ± 1.41 |
| Day 29 (n=98, 95, 98) | 2.26 ± 1.87 | 4.51 ± 2.60 | 1.70 ± 1.88 |
| Day 57 (n=94 89 96) | 5.96 ± 2.13 | 7.28 ± 3.38 | 2.38 ± 2.27 |
| Day 85 (n=90, 91, 93) | 8.56 ± 2.88 | 6.20 ± 3.30 | 2.89 ± 2.30 |
| Day 113 (n=91, 83, 91) | 5.31 ± 2.73 | 10.23 ± 4.11 | 4.12 ± 2.70 |
| Day 141 (n=89, 83, 90) | 8.33 ± 2.74 | 7.90 ± 3.00 | 3.62 ± 2.28 |
| Day 169 (n=83, 82, 85) | 8.12 ± 2.70 | 10.55 ± 3.46 | 7.34 ± 2.31 |
| Day 197 (n=84, 81, 87) | 7.71 ± 2.73 | 10.67 ± 2.78 | 6.79 ± 2.25 |
| Day 225 (n=84, 81, 84) | 7.32 ± 2.78 | 7.72 ± 2.77 | 7.19 ± 2.23 |
| Day 253 (n=81, 76, 81) | 4.70 ± 3.02 | 7.22 ± 3.50 | 5.86 ± 2.39 |
| Day 281 (n=78, 77, 80) | 5.68 ± 2.83 | 6.81 ± 3.37 | 5.38 ± 2.30 |
| Day 309 (n=77, 76, 78) | 6.34 ± 2.89 | 9.53 ± 2.95 | 6.00 ± 2.57 |
| Day 337 (n=74, 75, 79) | 5.34 ± 2.60 | 10.15 ± 2.74 | 4.39 ± 2.86 |
| Day 365 (n=75, 73, 78) | 5.17 ± 2.75 | 11.03 ± 2.85 | 5.68 ± 2.49 |
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as nonreversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Baseline (n=68, 67, 70) | 0.34 ± 0.68 | 0.27 ± 0.62 | 0.29 ± 0.73 |
| Post Baseline Mean (n=68, 67, 70) | 0.53 ± 1.04 | 0.40 ± 0.80 | 0.44 ± 0.81 |
PR is either CRR, Partial Renal Response(PRR),or no Response(NR). CRR= Serum creatinine(SC)is normal, Inactive urinary sediment, No cellular casts, Urinary protein/creatinine (UPCR) ratio \<56.5 mg/mmoL; PRR= SC is normal OR SC not \>25% above BL, RBCs at reference range, UPCR \<56.5 mg/mmoL OR ≥50% improvement in UPCR with one of the following: UPCR \<113 or \<339 mg/mmoL, based on the BL ratio; NR= Not achieving either a CRR or a PRR. Participants achieved response if criteria at both months 11 and 12 (Days 337 and 365) were met. Participants who Early discontinuations were categorized as NR.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| No Renal Response | 61 | 69 | 66 |
| Partial Renal Response | 14 | 9 | 14 |
| Complete Renal Response | 24 | 21 | 20 |
RR is defined as meeting BOTH of the following criteria:RENAL FUNCTION: Less than or equal to 25% increase from baseline;PROTEINURIA: Greater than or equal to 50% improvement in the urine protein/creatinine ratio with one of the following - urine protein/creatinine ratio (UPCR) \<113 mg/mmol,, if the baseline ratio was \<=339 mg/mmol OR UPCR \<339 mg/mmol,if the baseline ratio \> 339 mg/mmol. A participant was considered as achieving RR if response criteria at both months 11 and 12 (Days 337 and 365, respectively) were met. For 95% CI within each group, normal approximation is used if n\>=5.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Number of Participants Achieving Renal Response (RR) at Month 12 During Short-term Period | 45 (35.6 to 55.3) | 39 (29.8 to 49.0) | 33 (23.8 to 42.2) |
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity. Change from baseline=Postbaseline - baseline value.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Change in SLICC/ACR Damage Index From Baseline During Short-term Period | 0.17 ± 0.06 | 0.11 ± 0.06 | 0.13 ± 0.06 |
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Baseline (Day 1) for Day 85 (n=89, 91, 93) | 42.18 ± 9.07 | 43.80 ± 8.42 | 42.68 ± 8.93 |
| Baseline (Day 1) for Day 169 (n=92, 94, 96) | 42.04 ± 9.08 | 44.17 ± 8.55 | 42.48 ± 8.90 |
| Baseline (Day 1) for Day 253 (n=92, 94, 96) | 42.04 ± 9.08 | 44.17 ± 8.55 | 42.48 ± 8.90 |
| Baseline (Day 1) for Day 365 (n=92, 94, 96) | 42.04 ± 9.08 | 44.17 ± 8.55 | 42.48 ± 8.90 |
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 85 (n=89, 91, 93) | 4.17 ± 0.82 | 2.61 ± 0.81 | 2.86 ± 0.80 |
| Day 169 (n=92, 94, 96) | 4.18 ± 0.85 | 4.07 ± 0.84 | 3.39 ± 0.83 |
| Day 253 (n=92, 94, 96) | 4.23 ± 0.92 | 4.80 ± 0.91 | 3.45 ± 0.90 |
| Day 365 (n=92, 94, 96) | 4.24 ± 0.91 | 5.00 ± 0.91 | 3.77 ± 0.90 |
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Baseline (Day 1) for Day 85 ( n=89, 91, 93) | 42.18 ± 9.07 | 43.80 ± 8.42 | 42.68 ± 8.93 |
| Baseline (Day 1) for Day 169 (n=92,94,96) | 44.08 ± 10.93 | 41.84 ± 11.50 | 42.59 ± 12.22 |
| Baseline (Day 1) for Day 253 ( n=92,94,96) | 44.08 ± 10.93 | 41.84 ± 11.50 | 42.59 ± 12.22 |
| Baseline (Day 1) for Day 365 ( n=92,94,96) | 44.08 ± 10.93 | 41.84 ± 11.50 | 42.59 ± 12.22 |
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 85 (n=89, 91, 93) | 1.07 ± 1.11 | 3.10 ± 1.08 | 1.87 ± 1.08 |
| Day 169 (n=92, 94, 96) | 2.90 ± 1.01 | 5.08 ± 1.00 | 3.69 ± 0.99 |
| Day 253 (n=92, 94, 96) | 2.45 ± 1.00 | 4.83 ± 0.99 | 2.99 ± 0.98 |
| Day 365 (n=92, 94, 96) | 2.62 ± 0.96 | 4.23 ± 0.95 | 2.84 ± 0.94 |
A visual analogue scale (VAS) is a psychometric response scale for measurement of subjective characteristics or attitudes that cannot be directly measured. The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Baseline (Day 1) for Day 85 (n=90, 94, 95) | 48.86 ± 25.97 | 41.95 ± 22.81 | 48.93 ± 25.47 |
| Baseline (Day 1) for Day 169 (n=92, 94, 97) | 48.80 ± 25.96 | 41.95 ± 22.81 | 48.25 ± 25.68 |
| Baseline (Day 1) for Day 253 (n=92, 94, 97) | 48.80 ± 25.96 | 41.95 ± 22.81 | 48.25 ± 25.68 |
| Baseline (Day 1) for Day 365 (n=92, 94, 97) | 48.80 ± 25.96 | 41.95 ± 22.81 | 48.25 ± 25.68 |
A visual analogue scale is a psychometric response scale for measurement of subjective characteristics or attitudes that cannot be directly measured. The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 85 (n=90, 94, 95) | -9.18 ± 2.37 | -4.94 ± 2.33 | -6.20 ± 2.33 |
| Day 169 (n=92, 94, 97) | -7.18 ± 2.49 | -9.52 ± 2.48 | -4.71 ± 2.44 |
| Day 253 (n=92, 94, 97) | -8.78 ± 2.59 | -11.90 ± 2.57 | -7.35 ± 2.53 |
| Day 365 (n=92, 94, 97) | -12.21 ± 2.70 | -12.32 ± 2.69 | -11.07 ± 2.65 |
The reduction of fatigue assessed by Fatigue Severity Scale (FSS). The FSS questionnaire is comprised of 9 statements inquiring about the examinee's sleep habits over the preceding week. Participants are asked to rate their level of agreement (toward seven) or disagreement (toward zero) with the nine statements. A score of 36 and above (out of a maximum of 63) indicates the presence of significant fatigue.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Baseline (Day 1) for Day 85 (n=90, 94, 95) | 40.60 ± 13.75 | 39.14 ± 13.54 | 39.64 ± 13.00 |
| Baseline (Day 1) for Day 169 (n=92, 94, 97) | 40.41 ± 13.67 | 39.14 ± 13.54 | 39.59 ± 12.87 |
| Baseline (Day 1) for Day 253 ( n=92, 94, 97) | 40.41 ± 13.67 | 39.14 ± 13.54 | 39.59 ± 12.87 |
| Baseline (Day 1) for Day 365 ( n=92, 94, 97) | 40.41 ± 13.67 | 39.14 ± 13.54 | 39.59 ± 12.87 |
The reduction of fatigue assessed by Fatigue Severity Scale (FSS). The FSS questionnaire is comprised of 9 statements inquiring about the examinee's sleep habits over the preceding week. Participants are asked to rate their level of agreement (toward seven) or disagreement (toward zero) with the nine statements. A score of 36 and above (out of a maximum of 63) indicates the presence of significant fatigue.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 85 (n=90, 94, 95) | -1.54 ± 1.20 | -1.40 ± 1.18 | -0.67 ± 1.18 |
| Day 169 (n=92, 94, 97) | -2.68 ± 1.15 | -1.69 ± 1.14 | -1.08 ± 1.13 |
| Day 253 ( n=92, 94, 97) | -3.54 ± 1.12 | -2.95 ± 1.11 | -3.06 ± 1.09 |
| Day 365 ( n=92, 94, 97) | -4.20 ± 1.21 | -3.21 ± 1.20 | -4.79 ± 1.19 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=possibly, probably, or certainly related to and of unknown relationship to study drug.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Deaths | 5 | 2 | 7 |
| SAEs | 33 | 28 | 31 |
| Related SAEs | 20 | 19 | 15 |
| AEs | 93 | 89 | 94 |
| Related AEs | 61 | 53 | 55 |
| Discontinued due to AEs | 14 | 13 | 9 |
AEs of special interest were prospectively identified to be those that may be associated with the use of immunomodulatory agents. They are a subset of all AEs and may be either serious or non-serious.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Infections and Infestations | 75 | 70 | 75 |
| Malignancies | 0 | 1 | 1 |
| Autoimmune Disorders | 4 | 5 | 3 |
| Acute Infusional AEs | 23 | 18 | 17 |
| Peri-infusional AEs | 23 | 18 | 17 |
LLN=lower limit of normal; ULN=upper limit of normal; PTV=pretreatment value. Normal ranges are provided by the Central Laboratory and may vary according to sex and age. Low(↓)Hemoglobin:\>3g/dL decrease from PTV; ↓Hematocrit:\<0.75xPTV;↓Erythrocyte count:\<0.75xPTV; high(↑)Platelet count:\>1.5xULN;↓Platelet count:\<0.67xLLN;↓Leukocyte count:\<0.75X LLN;↑Leukocyte count:\>1.25xULN;↓Absolute(AB)Neutrophils+Bands:\<1.00x10\^3c/uL;↑AB Lymphocyte count:\>7.50x10\^3 c/uL; ↓AB lymphocyte count:\<0.750x10\^3 c/uL;↑AB monocyte count:\>2000/mm\^3;↑AB basophil count:\>400/mm\^3;↑AB eosinophil count:\>0.750x10\^3 c/uL.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Low Hemoglobin (n=98, 98, 99) | 6 | 3 | 9 |
| Low Hematocrit (n=97, 98, 99) | 5 | 1 | 7 |
| Low Erythrocyte Count (n=98, 98, 99) | 4 | 1 | 7 |
| High Platelet Count (n=98, 98, 98) | 1 | 0 | 1 |
| Low Platelet Count (n=98, 98, 98) | 1 | 3 | 1 |
| High Leukocyte Count (n=98, 98, 99) | 15 | 10 | 11 |
| Low Leukocyte Count (n=98,98,99) | 13 | 18 | 16 |
| Low Absolute Neutrophils + Bands (n=98,98,99) | 1 | 2 | 7 |
| High Absolute Lymphocyte Count (n=98,98,99) | 0 | 2 | 0 |
| Low Absolute Lymphocyte Count (n=98, 98, 99) | 47 | 32 | 53 |
| High Absolute Monocyte Count (n=98, 98, 99) | 1 | 1 | 1 |
| High Absolute Basophil Count (n=98, 98, 99) | 0 | 0 | 0 |
| High Absolute Eosinophil Count (n=98, 98, 99) | 0 | 3 | 0 |
LLN=lower limit of normal; ULN=upper limit of normal; PTV=pretreatment value. Normal ranges are provided by the Central Laboratory and may vary according to sex and age. ↑Serum Sodium:\>1.05x ULN;↓Serum Potassium:\<0.9x LLN;↑Serum Potassium:\>1.1x ULN;↓Total Calcium:\<0.8X LLN;↑Total Calcium:\>1.2x ULN; ↓Serum Glucose(SG):\<65 mg/dL;↑SG:\>220 mg/dL;↓Fasting SG:\<0.8x LLN;↑Fasting SG:\>1.5x ULN;↓Total Protein:\<0.9x LLN;↓Albumin:\<0.9x LLN;↑Total Cholesterol:\>2x PTV;↑Triglycerides:\>=2.5x ULN;↑Fasting Triglycerides:\>=2x ULN
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| High Serum Sodium (n=98, 98, 99) | 1 | 2 | 0 |
| Low Serum Potassium (n=98, 98, 99) | 12 | 14 | 15 |
| High Serum Potassium (n=98, 98, 99) | 4 | 0 | 2 |
| Low Total Calcium (n=98, 98, 99) | 0 | 1 | 1 |
| High Total Calcium (n=98, 98, 99) | 1 | 2 | 1 |
| Low Serum Glucose (n=98, 98, 99) | 12 | 16 | 18 |
| High Serum Glucose (n=98, 98, 99) | 2 | 2 | 2 |
| Low Fasting Serum Glucose (n=72, 73, 68) | 3 | 2 | 0 |
| High Fasting Serum Glucose (n=72, 73, 68) | 1 | 1 | 0 |
| Low Total Protein (n=98, 98, 99) | 18 | 18 | 25 |
| Low Albumin (n=98, 98, 99) | 10 | 6 | 4 |
| High Total Cholesterol (n=93,93,96) | 2 | 0 | 1 |
| High Triglycerides (n=71, 79, 75) | 2 | 0 | 0 |
| High Fasting Triglycerides (n=65, 64, 63) | 3 | 0 | 0 |
ULN=upper limit of normal; PTV=pretreatment value. Normal ranges are provided by the Central Laboratory and may vary according to sex and age. Alkaline Phosphatase:\>2x ULN; ↑Aspartate Aminotransferase: \>3x ULN; ↑Alanine Aminotransferase : \>3x ULN; G-Glutamyl Transferase : \>2x ULN; ↑Total Bilirubin : \>2x ULN or if PTV \> ULN then \> 4x PTV; ↑Blood Urea Nitrogen \>2x PTV; ↑Creatinine \>1.5x PTV.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| High Alkaline Phosphatase | 1 | 1 | 1 |
| High Aspartate Aminotransferase | 2 | 0 | 0 |
| High Alanine Aminotransferase | 7 | 4 | 1 |
| High G-Glutamyl Transferase | 7 | 7 | 5 |
| High Total Bilirubin | 0 | 0 | 0 |
| High Blood Urea Nitrogen | 5 | 1 | 6 |
| High Creatinine | 16 | 6 | 12 |
PTV=pretreatment value. Criteria for marked abnormality: Protein, glucose, blood, leukocyte esterase , if missing PTV then use \>=2+ (or, if value \>=4, or if PTV=0 or 0.5, \>=2 or if PTV=1, \>=3, or if PTV=2 or 3, \>=4).
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Urine Protein (n=99,98,99) | 6 | 3 | 8 |
| Urine Glucose (n=99,98,99) | 1 | 3 | 0 |
| Urine Blood (n=99,98,99) | 16 | 19 | 17 |
| Urine Leukocyte esterase (n=85,91,90) | 10 | 8 | 8 |
| mmHg | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 1: SBP-before infusion; n=76,81,73 | 128.2 ± 16.34 | 127.8 ± 15.86 | 126.2 ± 16.88 |
| Day 1: SBP-1hour after infusion; n=69,78,70 | 127.7 ± 17.60 | 126.7 ± 15.53 | 126.0 ± 18.20 |
| Day 1: SBP-2.5 hours after infusion; n=79,81,76 | 127.1 ± 16.92 | 127.8 ± 12.55 | 126.2 ± 15.82 |
| Day 15: SBP-before infusion; n=78,78,74 | 127.6 ± 18.71 | 125.5 ± 16.42 | 129.2 ± 17.80 |
| Day 15: SBP- 1hour after infusion; n=72,75,71 | 126.9 ± 14.79 | 125.9 ± 16.35 | 128.2 ± 14.65 |
| Day 15: SBP-2.5 hours after infusion; n=80,78,78 | 130.1 ± 14.99 | 124.9 ± 15.08 | 131.2 ± 15.58 |
| Day 29: SBP-before infusion; n=77,79,75 | 125.6 ± 13.52 | 126.2 ± 15.31 | 126.9 ± 14.79 |
| Day 29: SBP-1hour after infusion; n=72,75,74 | 126.2 ± 12.92 | 125.9 ± 15.85 | 128.6 ± 15.34 |
| Day 29: SBP-2.5 hours after infusion; n=80,79,82 | 126.3 ± 13.77 | 126.4 ± 14.86 | 127.6 ± 14.54 |
| Day 57: SBP-before infusion; n=74,76,70 | 126.4 ± 15.47 | 124.8 ± 16.21 | 123.0 ± 13.21 |
| Day 57: SBP-1hour after infusion; n=74,69,68 | 124.6 ± 13.40 | 122.1 ± 16.73 | 124.4 ± 11.22 |
| Day 57: SBP-2.5 hours after infusion; n=81,73,73 | 127.0 ± 13.04 | 123.6 ± 14.43 | 126.1 ± 14.29 |
| Day 85: SBP- before infusion; n=73,71,67 | 122.0 ± 13.52 | 118.7 ± 12.85 | 122.2 ± 13.67 |
| Day 85: SBP-1hour after infusion; n=73,69,72 | 121.8 ± 13.28 | 119.6 ± 13.59 | 122.0 ± 14.23 |
| Day 113: SBP-before infusion; n=72,70,70 | 122.6 ± 18.07 | 121.7 ± 14.26 | 119.9 ± 14.16 |
| Day 113: SBP-1hour after infusion; n=75,70,75 | 121.5 ± 16.81 | 121.0 ± 13.13 | 120.1 ± 14.69 |
| Day 141: SBP-before infusion; n=66,70,66 | 121.4 ± 15.94 | 119.2 ± 15.67 | 118.8 ± 14.26 |
| Day 141: SBP-1hour after infusion; n=72,71,70 | 120.9 ± 18.11 | 117.9 ± 15.32 | 120.4 ± 13.26 |
| Day 169: SBP-before infusion; n=70,70,66 | 118.5 ± 16.30 | 117.6 ± 12.13 | 118.6 ± 14.65 |
| Day 169: SBP-1hour after infusion; n=75,71,71 | 120.3 ± 18.74 | 118.2 ± 11.83 | 118.9 ± 14.15 |
| Day 197: SBP-before infusion; n=68,70,64 | 119.0 ± 15.58 | 118.9 ± 14.72 | 118.7 ± 12.34 |
| Day 197: SBP-1hour after infusion; n=72,73,70 | 117.7 ± 14.76 | 117.4 ± 13.10 | 120.4 ± 15.29 |
| Day 225: SBP-before infusion; n=70,64,63 | 118.2 ± 14.53 | 118.8 ± 13.51 | 119.5 ± 13.20 |
| Day 225: SBP-1hour after infusion; n=72,65,68 | 116.6 ± 15.82 | 119.5 ± 14.60 | 118.8 ± 12.83 |
| Day 253: SBP-before infusion; n=63,66,63 | 120.6 ± 15.13 | 120.2 ± 17.21 | 120.9 ± 14.17 |
| Day 253: SBP-1hour after infusion; n=69,67,67 | 118.1 ± 14.81 | 117.1 ± 15.02 | 119.7 ± 14.16 |
| Day 281: SBP-before infusion; n=63,66,58 | 120.7 ± 14.02 | 116.5 ± 14.30 | 120.3 ± 12.78 |
| Day 281: SBP-1hour after infusion; n=66,65,64 | 119.5 ± 15.28 | 119.4 ± 13.70 | 121.0 ± 12.48 |
| Day 309: SBP-before infusion; n=63,63,59 | 119.4 ± 14.18 | 116.3 ± 14.33 | 120.5 ± 15.32 |
| Day 309: SBP-1hour after infusion; n=67,66,64 | 119.6 ± 13.47 | 114.1 ± 14.97 | 119.2 ± 15.73 |
| Day 337: SBP-before infusion; n=63,64,61 | 119.9 ± 12.52 | 117.3 ± 14.71 | 119.3 ± 14.49 |
| Day 337: SBP-1hour after infusion; n=68,65,67 | 120.4 ± 12.97 | 117.7 ± 16.48 | 119.3 ± 13.67 |
| mm Hg | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 1: DBP-before infusion; n=76,81,73 | 80.8 ± 11.69 | 80.6 ± 12.57 | 80.4 ± 12.40 |
| Day 1: DBP-1hour after infusion; n=69,78,70 | 79.6 ± 13.57 | 79.6 ± 12.59 | 80.1 ± 13.34 |
| Day 1: DBP-2.5 hours after infusion; n=79,81,76 | 79.3 ± 12.73 | 79.0 ± 10.93 | 80.9 ± 11.24 |
| Day 15: DBP-before infusion; n=78,78,74 | 81.1 ± 12.56 | 80.0 ± 12.89 | 82.6 ± 12.89 |
| Day 15: DBP- 1hour after infusion; n=72,75,71 | 79.6 ± 10.87 | 78.7 ± 11.58 | 80.4 ± 10.96 |
| Day 15: DBP-2.5 hours after infusion; n=80,78,78 | 81.4 ± 11.79 | 78.0 ± 11.27 | 82.8 ± 11.38 |
| Day 29: DBP-before infusion; n=77,79,75 | 79.6 ± 11.08 | 78.8 ± 12.14 | 81.3 ± 9.95 |
| Day 29: DBP-1hour after infusion; n=72,75,74 | 79.9 ± 10.06 | 78.0 ± 12.84 | 80.8 ± 10.36 |
| Day 29: DBP-2.5 hours after infusion; n=80,79,82 | 78.5 ± 9.75 | 78.2 ± 11.62 | 79.5 ± 11.08 |
| Day 57: DBP-before infusion; n=74,76,70 | 80.0 ± 10.98 | 78.7 ± 10.69 | 78.7 ± 10.59 |
| Day 57: DBP-1hour after infusion; n=74,69,68 | 78.9 ± 11.23 | 75.3 ± 11.87 | 78.7 ± 9.25 |
| Day 57: DBP-2.5 hours after infusion; n=81,73,73 | 79.5 ± 10.06 | 76.1 ± 10.49 | 80.2 ± 9.60 |
| Day 85: DBP- before infusion; n=73,71,67 | 79.7 ± 11.01 | 75.2 ± 9.39 | 78.7 ± 9.94 |
| Day 85: DBP-1hour after infusion; n=73,69,72 | 78.1 ± 11.72 | 75.6 ± 9.29 | 78.1 ± 10.58 |
| Day 113: DBP-before infusion; n=72,70,70 | 78.5 ± 13.75 | 77.0 ± 10.58 | 76.7 ± 11.62 |
| Day 113: DBP-1hour after infusion; n=75,70,75 | 76.1 ± 12.13 | 76.3 ± 10.74 | 76.9 ± 11.61 |
| Day 141: DBP-before infusion; n=66,70,66 | 78.8 ± 11.32 | 74.0 ± 12.08 | 76.5 ± 11.48 |
| Day 141: DBP-1hour after infusion; n=72,71,70 | 77.8 ± 11.24 | 74.7 ± 11.54 | 76.1 ± 11.69 |
| Day 169: DBP-before infusion; n=70,70,66 | 75.5 ± 12.96 | 74.1 ± 10.18 | 77.0 ± 13.16 |
| Day 169: DBP-1hour after infusion; n=75,71,71 | 76.5 ± 13.24 | 74.4 ± 9.41 | 76.4 ± 12.81 |
| Day 197: DBP-before infusion; n=68,70,64 | 76.8 ± 11.29 | 75.8 ± 10.79 | 75.8 ± 11.16 |
| Day 197: DBP-1hour after infusion; n=72,73,70 | 76.1 ± 11.63 | 74.5 ± 10.55 | 75.4 ± 12.21 |
| Day 225: DBP-before infusion; n=70,64,63 | 74.5 ± 12.39 | 73.6 ± 9.68 | 75.7 ± 10.77 |
| Day 225: DBP-1hour after infusion; n=72,65,68 | 75.0 ± 11.67 | 74.5 ± 10.95 | 76.0 ± 10.28 |
| Day 253: DBP-before infusion; n=63,66,63 | 76.1 ± 11.54 | 75.9 ± 11.27 | 77.1 ± 10.26 |
| Day 253: DBP-1hour after infusion; n=69,67,67 | 74.5 ± 11.51 | 74.9 ± 10.25 | 75.7 ± 10.20 |
| Day 281: DBP-before infusion; n=63,66,58 | 77.6 ± 10.89 | 73.3 ± 9.50 | 76.6 ± 9.31 |
| Day 281: DBP-1hour after infusion; n=66,65,64 | 75.9 ± 10.49 | 74.5 ± 9.73 | 76.6 ± 10.15 |
| Day 309: DBP-before infusion; n=63,63,59 | 78.1 ± 9.73 | 72.9 ± 8.90 | 77.4 ± 11.83 |
| Day 309: DBP-1hour after infusion; n=67,66,64 | 76.4 ± 10.81 | 72.9 ± 9.86 | 76.6 ± 10.75 |
| Day 337: DBP-before infusion; n=63,64,61 | 78.0 ± 10.54 | 73.4 ± 9.52 | 76.2 ± 10.65 |
| Day 337: DBP-1hour after infusion; n=68,65,67 | 78.1 ± 9.72 | 73.3 ± 9.82 | 76.1 ± 11.19 |
| beats per minute | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 1: before infusion; n=99,98,100 | 82.4 ± 11.17 | 79.2 ± 10.84 | 82.6 ± 12.11 |
| Day 1: 1hour after infusion; n=98,98,98 | 81.3 ± 11.08 | 79.6 ± 9.71 | 81.9 ± 10.64 |
| Day 1: 2.5 hours after infusion; n=97,96,96 | 81.8 ± 11.38 | 82.2 ± 11.25 | 83.8 ± 11.51 |
| Day 15: before infusion; n=97,93,99 | 83.1 ± 12.08 | 81.0 ± 11.31 | 83.7 ± 12.84 |
| Day 15: 1hour after infusion; n=96,94,98 | 81.3 ± 12.21 | 80.1 ± 11.31 | 82.6 ± 11.70 |
| Day 15: 2.5 hours after infusion; n=93,92,95 | 81.5 ± 11.18 | 81.7 ± 9.88 | 84.7 ± 12.65 |
| Day 29: before infusion; n=94,93,99 | 83.7 ± 12.13 | 80.8 ± 11.85 | 83.0 ± 12.91 |
| Day 29: 1hour after infusion; n=93,92,99 | 81.7 ± 12.23 | 79.9 ± 9.60 | 81.7 ± 11.00 |
| Day 29: 2.5 hours after infusion; n=92,90,97 | 81.3 ± 10.26 | 82.1 ± 9.56 | 84.7 ± 11.41 |
| Day 57: before infusion; n=93,88,84 | 83.4 ± 11.04 | 82.2 ± 12.09 | 82.8 ± 13.00 |
| Day 57: 1hour after infusion; n=93,84,94 | 81.0 ± 10.02 | 81.6 ± 10.52 | 81.8 ± 10.80 |
| Day 57: 2.5 hours after infusion; n=91,84,91 | 82.5 ± 10.13 | 83.4 ± 12.20 | 83.8 ± 11.09 |
| Day 85: before infusion; n=89,86,91 | 84.8 ± 12.35 | 82.3 ± 11.00 | 82.5 ± 10.99 |
| Day 85: 1hour after infusion; n=88,84,89 | 83.3 ± 11.02 | 80.4 ± 10.67 | 83.5 ± 9.50 |
| Day 113: before infusion; n=88,82,92 | 82.1 ± 11.46 | 80.4 ± 11.88 | 83.0 ± 11.78 |
| Day 113: 1hour after infusion; n=87,80,91 | 81.8 ± 10.64 | 80.2 ± 9.98 | 82.6 ± 10.62 |
| Day 141: before infusion; n=84,82,89 | 82.8 ± 11.75 | 79.3 ± 11.20 | 82.6 ± 12.74 |
| Day 141: 1hour after infusion; n=84,81,86 | 81.4 ± 10.92 | 79.1 ± 10.59 | 81.3 ± 11.30 |
| Day 169: before infusion; n=85,82,86 | 80.1 ± 10.01 | 78.0 ± 11.35 | 79.1 ± 10.95 |
| Day 169: 1hour after infusion; n=84,82,85 | 79.5 ± 10.43 | 78.8 ± 10.97 | 81.4 ± 12.30 |
| Day 197: before infusion; n=83,82,84 | 81.7 ± 10.54 | 78.1 ± 10.72 | 79.3 ± 11.58 |
| Day 197: 1hour after infusion; n=82,82,85 | 79.8 ± 9.84 | 78.7 ± 10.25 | 79.6 ± 11.77 |
| Day 225: before infusion; n=83,76,81 | 80.1 ± 10.04 | 77.6 ± 10.59 | 78.9 ± 10.00 |
| Day 225: 1hour after infusion; n=83,76,81 | 79.1 ± 9.86 | 78.0 ± 9.83 | 80.2 ± 10.03 |
| Day 253: before infusion; n=78,77,81 | 81.4 ± 11.32 | 79.1 ± 11.30 | 81.5 ± 12.17 |
| Day 253: 1hour after infusion; n=78,77,81 | 78.8 ± 9.01 | 79.3 ± 10.64 | 79.5 ± 10.91 |
| Day 281: before infusion; n=75,76,77 | 80.1 ± 10.56 | 78.3 ± 11.16 | 79.3 ± 10.24 |
| Day 281: 1hour after infusion; n=74,76,76 | 78.0 ± 9.93 | 77.6 ± 9.46 | 78.7 ± 9.95 |
| Day 309: before infusion; n=76,75,77 | 79.8 ± 10.89 | 76.5 ± 10.07 | 78.2 ± 10.66 |
| Day 309: 1hour after infusion; n=76,74,77 | 77.9 ± 10.40 | 77.4 ± 9.81 | 78.4 ± 11.49 |
| Day 337: before infusion; n=73,75,80 | 78.5 ± 11.77 | 76.4 ± 9.95 | 78.9 ± 11.50 |
| Day 337: 1hour after infusion; n=73,73,79 | 77.6 ± 9.85 | 77.4 ± 9.73 | 78.3 ± 11.11 |
| degree celcius | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 1: before infusion; n=99,98,99 | 36.6 ± 0.48 | 36.5 ± 0.42 | 36.5 ± 0.47 |
| Day 1: 1hour after infusion; n=98,96,97 | 36.6 ± 0.50 | 36.5 ± 0.46 | 36.6 ± 0.51 |
| Day 1: 2.5 hours after infusion; n=97,93,97 | 36.6 ± 0.45 | 36.5 ± 0.43 | 36.6 ± 0.49 |
| Day 15: before infusion; n=97,94,99 | 36.5 ± 0.50 | 36.5 ± 0.45 | 36.5 ± 0.47 |
| Day 15: 1hour after infusion; n=96,91,98 | 36.6 ± 0.47 | 36.5 ± 0.45 | 36.5 ± 0.53 |
| Day 15: 2.5 hours after infusion; n=93,91,95 | 36.6 ± 0.47 | 36.5 ± 0.44 | 36.6 ± 0.53 |
| Day 29: before infusion; n=94,93,99 | 36.5 ± 0.51 | 36.4 ± 0.489 | 36.5 ± 0.48 |
| Day 29: 1hour after infusion; n=93,91,98 | 36.5 ± 0.50 | 36.5 ± 0.44 | 36.5 ± 0.49 |
| Day 29: 2.5 hours after infusion; n=92,90,97 | 36.5 ± 0.46 | 36.5 ± 0.47 | 36.5 ± 0.49 |
| Day 57: before infusion; n=93,88,93 | 36.5 ± 0.46 | 36.4 ± 0.50 | 36.5 ± 0.49 |
| Day 57: 1hour after infusion; n=93,83,94 | 36.1 ± 3.58 | 36.4 ± 0.46 | 36.6 ± 0.49 |
| Day 57: 2.5 hours after infusion; n=90,84,90 | 36.5 ± 0.41 | 36.5 ± 0.48 | 36.5 ± 0.53 |
| Day 85: before infusion; n=89,86,91 | 36.4 ± 0.52 | 36.4 ± 0.45 | 36.5 ± 0.45 |
| Day 85: 1hour after infusion; n=87,84,89 | 36.4 ± 0.51 | 36.4 ± 0.50 | 36.5 ± 0.49 |
| Day 113: before infusion; n=88,82,92 | 36.5 ± 0.60 | 36.4 ± 0.50 | 36.5 ± 0.54 |
| Day 113: 1hour after infusion; n=87,79,91 | 36.4 ± 0.49 | 36.4 ± 0.44 | 36.5 ± 0.51 |
| Day 141: before infusion; n=84,81,89 | 36.5 ± 0.50 | 36.4 ± 0.45 | 36.5 ± 0.47 |
| Day 141: 1hour after infusion; n=84,80,86 | 36.5 ± 0.45 | 36.4 ± 0.41 | 36.5 ± 0.49 |
| Day 169: before infusion; n=85,81,86 | 36.5 ± 0.52 | 36.4 ± 0.48 | 36.5 ± 0.46 |
| Day 169: 1hour after infusion; n=84,80,84 | 36.4 ± 0.47 | 36.4 ± 0.44 | 36.5 ± 0.46 |
| Day 197: before infusion; n=83,82,85 | 36.5 ± 0.58 | 36.3 ± 0.45 | 36.5 ± 0.45 |
| Day 197: 1hour after infusion; n=82,81,84 | 36.4 ± 0.61 | 36.3 ± 0.49 | 36.5 ± 0.48 |
| Day 225: before infusion; n=83,76,81 | 36.5 ± 0.56 | 36.4 ± 0.48 | 36.4 ± 0.55 |
| Day 225: 1hour after infusion; n=83,75,81 | 36.5 ± 0.56 | 36.4 ± 0.45 | 36.5 ± 0.54 |
| Day 253: before infusion; n=78,77,80 | 36.5 ± 0.52 | 36.4 ± 0.44 | 36.5 ± 0.46 |
| Day 253: 1hour after infusion; n=78,77,81 | 36.5 ± 0.54 | 36.4 ± 0.42 | 36.5 ± 0.49 |
| Day 281: before infusion; n=75,76,77 | 36.5 ± 0.49 | 36.4 ± 0.43 | 36.5 ± 0.49 |
| Day 281: 1hour after infusion; n=74,76,76 | 36.5 ± 0.51 | 36.4 ± 0.46 | 36.5 ± 0.47 |
| Day 309: before infusion; n=76,75,77 | 36.5 ± 0.49 | 36.3 ± 0.51 | 36.5 ± 0.54 |
| Day 309: 1hour after infusion; n=75,73,77 | 36.5 ± 0.51 | 36.4 ± 0.43 | 36.5 ± 0.54 |
| Day 337: before infusion; n=73,75,79 | 36.5 ± 0.47 | 36.4 ± 0.46 | 36.5 ± 0.50 |
| Day 337: 1hour after infusion; n=73,72,79 | 36.5 ± 0.59 | 36.4 ± 0.49 | 36.5 ± 0.52 |
A validated, sensitive electrochemiluminescence (ECL) immunoassay based on Meso-Scale Discovery instrumentation was used to evaluate immunogenicity. The ECL assay differentiated between two antibody specificities: (1) the 'Ig and/or Junction (Jn) Region' and (2) 'CLTA4 and possibly Ig'. A sample was considered positive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept with or without CTLA4-T.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| CTLA4 and possibly Ig; Day 169 (n=90) | 2 | 1 | — |
| CTLA4 and possibly Ig; Day 365 (n=74) | 1 | 0 | — |
| CTLA4 and possibly Ig;Overall on TRT visits (n=90) | 3 | 1 | — |
| CTLA4 and possibly Ig; Overall Post visits (n=20) | 7 | 5 | — |
| CTLA4 and possibly Ig; Overall (n=96) | 9 | 6 | — |
| Ig/Jn region; Day 169 (n=90) | 0 | 0 | — |
| Ig/Jn region; Day 365 (n=78) | 1 | 0 | — |
| Ig/Jn region; Overall on TRT visits (n=90) | 1 | 0 | — |
| Ig/Jn region; Overall on Post visits (n=20) | 0 | 1 | — |
| Ig/Jn region; Overall (n=95) | 1 | 1 | — |
A quantitative immunoglobulins (Igs) test is used to detect abnormal levels of the three major classes of Igs (IgG, IgA, and IgM). Abnormal test results typically indicate that there is something affecting the immune system which requires further testing.
| mg/dL | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Immunoglobulin IgA | 246.28 ± 99.55 | 218.04 ± 88.23 | 230.23 ± 107.34 |
| Immunoglobulin IgG | 939.80 ± 423.66 | 864.12 ± 459.44 | 1013.17 ± 516.24 |
| Immunoglobulin IgM | 100.96 ± 79.70 | 97.10 ± 55.18 | 98.49 ± 57.71 |
A quantitative immunoglobulin (Ig) test is used to detect abnormal levels of the 3 major classes of Ig (IgG, IgA, and IgM). Abnormal test results typically indicate that something is affecting the immune system and further testing is required. Please refer to Outcome 31 for the respective baseline values
| mg/dL | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Ig A (n=76, 73, 78) | -32.83 ± 8.47 | -34.48 ± 6.87 | -26.51 ± 8.20 |
| IgG (n=76, 73, 78) | 41.41 ± 47.17 | 27.21 ± 43.84 | 23.42 ± 49.07 |
| IgM (n=76, 73, 78) | -17.76 ± 5.28 | -19.38 ± 4.76 | -20.62 ± 4.89 |
The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS) defines complete response as a response meeting all of the following criteria: serum creatinine ≤upper limit of normal as defined by the central laboratory or ≤125% of the higher value at either screening or baseline; urine protein/creatinine ratio \<50 mg/mmoL; and prednisone or prednisone-equivalent dose tapered to 10 mg per day.
| participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 365 | 29 | 30 | 25 |
| Day 645 (n=55, 56, 61) | 27 | 28 | 25 |
Patient response=complete, partial, or no response. Complete response=serum creatinine (SCr) normal, inactive urinary sediment, no cellular casts, urinary protein/creatinine (UPCR) ratio\<56.5 mg/mmol. Partial response=SCr normal or ≤25% above baseline value, RBCs at reference range, UPCR \<56.5 mg/mmoL OR ≥50% improvement in UPCR with one of the following: UPCR \<113 or \<339 mg/mmoL, based on the baseline ratio. No response=Not achieving complete or partial response criteria.
| Participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 365 | 43 | 39 | 42 |
| Day 645 (n=59, 59, and 62) | 45 | 29 | 36 |
SLICC=Systemic Lupus International Collaborating Clinics; ACR=American College of Rheumatology. The SLICC/ACR Damage Index measures organ damage (nonreversible change, unrelated to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months unless otherwise stated. The index assesses 47 items in 12 systems: Ocular, Neuropsychiatric, Renal, Pulmonary, Cardiovascular, Gastrointestinal, Peripheral Vascular, Musculoskeletal, Skin, Premature Gonadal Failure, Diabetes, Malignancy. Scores range from 0 to 2, and the same lesion cannot be scored twice. If damage is noted for a particular item, it is scored 1. No damage is scored 0. Some items may score 2 points if they occur more than once, so that the maximum possible score is 47. Scores can only increase with time, but scores rarely reach over 12. It is usually completed (or updated) yearly.
| Units on a scale | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 365 (n=69, 65, 74) | -0.12 ± 0.06 | -0.17 ± 0.09 | -0.08 ± 0.07 |
| Day 729 (n=66, 65, 69) | -0.21 ± 0.10 | -0.28 ± 0.09 | -0.10 ± 0.08 |
| Day 1093 (n=41, 38, 44) | -.27 ± 0.13 | -0.16 ± 0.10 | 0.02 ± 0.08 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=possibly, probably, or certainly related to and of unknown relationship to study drug.
| Participants | Abatacept 10 mg/kg |
|---|---|
| Deaths | 5 |
| SAEs | 32 |
| Treatment-related SAEs | 14 |
| Discontinuations due to SAEs | 5 |
| AEs | 183 |
| Treatment-related AEs | 100 |
| Discontinuations due to AEs | 10 |
Collected in at least 1 sample. Assessment includes immunogenicity (detection of serum antibodies which bind to CTLA4-Ig in the in vitro assays) and exposure to corticosteroids
| Participants | Abatacept 10 mg/kg |
|---|---|
| Number of Participants With a Treatment-emergent Seropositive Result During the Long-term Extension Period | 17 |
Renal response=serum creatinine level ≤25% above baseline value and greater than or equal to 50% improvement in the urine protein/creatinine ratio with 1 of the following: urine protein/creatinine ratio (UPCR) \<113 mg/mmol, if the baseline ratio was \<= 339 mg/mmol OR UPCR \<339 mg/mmol,if the baseline ratio \>339 mg/mmol.
| participants | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| Day 365 | 46 | 66 | 74 |
| Day 645 (n=59, 59, 62) | 47 | 59 | 62 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Hemoglobin (g/dL): \>3g/dL decrease from preRX value. Hematocrit(%): \<0.75\*preRX. Erythrocytes (\*10\^6 c/uL): \<0.75\*preRX. Platelet count (\*10\^9 c/L): \<0.67\*LLN, or \>1.5\*ULN, or if preRX \<LLN, use \<0.5\*preRX and \<100,000/mm\^3. Leukocytes (\*10\^3 c/uL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\* preRX or \>ULN; if preRX\>ULN, use \>1.2\*preRX or \<LLN. Neutrophils + Bands (absolute) (\*10\^3 c/uL): If value \<1.0\*10\^3 or if value \>7.50\*10\^3 c/uL. Monocytes (absolute) (\*10\^3 c/uL): If value \>2000/mm\^3. Basophils (absolute)(\*10\^3 c/uL): If value \>.750\*10\^3 c/uL. Eosinophils (absolute) (\*10\^3 c/uL): If value \>.750\*10\^3 c/uL. ALP (U/L): \>2\*ULN, or if preRX\>ULN, use \>3\* preRX. AST (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX. ALT (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX. GGT (U/L):\>2\*ULN, or if preRX \>ULN, use \>3\*preRX. Bilirubin, total (mg/dL): \>2\*ULN, or if preRX\>ULN, use \>4\*preRX. BUN (mg/dL): \>1.5\*preRX.
| Participants | Abatacept 10 mg/kg |
|---|---|
| Hemoglobin (low) | 13 |
| Hemoglobin (high) | NA |
| Hematocrit (n=210) (low) | 11 |
| Hematocrit (n=210) (high) | NA |
| Erythrocytes (low) | 10 |
| Erythrocytes (high) | NA |
| Platelet count (n=210) (low) | 1 |
| Platelet count (n=210) (high) | 0 |
| Leukocytes (low) | 40 |
| Leukocytes (high) | 9 |
| Neutrophils + Bands (absolute) (low) | 4 |
| Neutrophils + Bands (absolute) (high) | NA |
| Lymphocytes (absolute) (low) | 59 |
| Lymphocytes (absolute) (high) | 0 |
| Monocytes (absolute) (low) | NA |
| Monocytes (absolute) (high) | 0 |
| Basophils (absolute) (low) | NA |
| Basophils (absolute) (high) | 0 |
| Eosinophils (absolute) (low) | NA |
| Eosinophils (absolute) (high) | 8 |
| Alkaline phosphatase (ALP) (low) | NA |
| ALP (high) | 3 |
| Aspartate aminotransferase (AST) (low) | NA |
| AST (high) | 3 |
| Alanine aminotransferase (ALT) (low) | NA |
| ALT (high) | 5 |
| G-glutamyl transferase (GGT) (low) | NA |
| GGT (high) | 14 |
| Bilirubin, total (low) | NA |
| Bilirubin, total (high) | 0 |
| Blood urea nitrogen (BUN) (low) | NA |
| BUN (high) | 9 |
| Creatinine (low) | NA |
| Creatinine (high) | 16 |
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium, serum (mEq/L): \<0.95\*LLN or \>1.05\*ULN, or if preRX\<LLN, use \<0.95\*preRX or \>ULN if preRX\>ULN, use \>1.05\*preRX or \<LLN. Potassium, serum (mEq/L): \<0.9\* LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN. Chloride, serum (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRX\<LLN, use \<0.9\*preRX or \>ULN. Calcium, total (mg/dL): \<0.8\*LLN or \>1.2\*ULN, or if preRX\<LLN, use \<0.75\*preRX or \>ULN if preRX\>ULN, use \>1.25\*preRX or \<LLN. Glucose, serum (mg/dL): \<65 mg/dL, or \>220 mg/dL. Glucose, fasting serum (mg/dL): \<0.8\*LLN or \>1.5\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN if preRX\>ULN, use \>2.0\*preRX or \<LLN. Albumin (g/dL): \<0.9\*LLN, or if preRX \<LLN, use \<0.75\*preRX. Cholesterol, total (mg/dL): \>2\*preRX. Triglycerides (mg/dL): \>=2.5\*ULN, or if preRX\>ULN, use \>=2.5\*preRX. Triglycerides, fasting (mg/dL): \>=2\*ULN, or if preRX\>ULN, use \>2.0\*preRX.
| Participants | Abatacept 10 mg/kg |
|---|---|
| Sodium, serum (low) | 1 |
| Sodium, serum (high) | 2 |
| Potassium, serum (n=210) (low) | 11 |
| Potassium, serum (n=210) (high) | 3 |
| Chloride, serum (low) | 0 |
| Chloride, serum (high) | 0 |
| Calcium, total (n=210) (low) | 1 |
| Calcium, total (n=210) (high) | 2 |
| Glucose, serum (low) | 23 |
| Glucose, serum (high) | 2 |
| Glucose, fasting serum (low) (n=143) | 2 |
| Glucose, fasting serum (high) (n=143) | 2 |
| Protein, total (low) | 19 |
| Protein, total (high) | 0 |
| Albumin (low) | 12 |
| Albumin (high) | NA |
| Cholesterol, total (low) (n=32) | 32 |
| Cholesterol, total (high) (n=32) | NA |
| Triglycerides (low) (n=20) | 20 |
| Triglycerides (high) (n=20) | NA |
| Triglycerides, fasting (low) (n=18) | 18 |
| Triglycerides, fasting (high) (n=18) | NA |
| Protein, urine (low) | NA |
| Protein, urine (high) | 9 |
| Glucose, urine (low) | NA |
| Glucose, urine (high) | 1 |
| Blood, urine (low) | NA |
| Blood, urine (high) | 35 |
| Leukocyte esterase, urine (low) (n=185) | NA |
| Leukocyte esterase, urine (high) (n=185) | 27 |
preRX=pretreatment. Protein, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX =0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 OR 3 then use \>=4. Glucose, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 or 3, use \>=4. Blood, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX =0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 or 3, use \>=4. Leukocyte esterase, urine: If missing preRX, use \>=2, or if value \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3, or if preRX=2 or 3, use \>=4.
| Participants | Abatacept 10 mg/kg |
|---|---|
| Protein, urine (low) | NA |
| Protein, urine (high) | 9 |
| Glucose, urine (low) | NA |
| Glucose, urine (high) | 1 |
| Blood, urine (low) | NA |
| Blood, urine (high) | 35 |
| Leukocyte esterase, urine (low) (n=185) | NA |
| Leukocyte esterase, urine (high) (n=185) | 27 |
Collected over Day 1 of Double-blind Period to within 56 days after last infusion of Double-blind Period or first infusion of Open-label Period, whichever occurred first.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept 30/10 mg/kg | — | 33/99 (33.3%) | 83/99 (83.8%) |
| Abatacept 10/10 mg/kg | — | 28/99 (28.3%) | 75/99 (75.8%) |
| Placebo | — | 31/100 (31%) | 84/99 (84.8%) |
| Event | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| HERPES ZOSTERInfections and infestations | 3/99 | 6/99 | 0/100 |
| GASTROENTERITISInfections and infestations | 5/99 | 1/99 | 2/100 |
| PNEUMONIAInfections and infestations | 4/99 | 4/99 | 3/100 |
| SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders | 1/99 | 2/99 | 4/100 |
| URINARY TRACT INFECTIONInfections and infestations | 0/99 | 2/99 | 2/100 |
| RENAL FAILURERenal and urinary disorders | 2/99 | 1/99 | 0/100 |
| MYOCARDITISCardiac disorders | 2/99 | 0/99 | 0/100 |
| CONVULSIONNervous system disorders | 0/99 | 2/99 | 0/100 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/99 | 1/99 | 2/100 |
| BRONCHOPNEUMONIAInfections and infestations | 0/99 | 0/99 | 2/100 |
| Event | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 30/99 | 29/99 | 32/99 |
| HEADACHENervous system disorders | 21/99 | 11/99 | 15/99 |
| DIARRHOEAGastrointestinal disorders | 13/99 | 11/99 | 19/99 |
| URINARY TRACT INFECTIONInfections and infestations | 9/99 | 10/99 | 17/99 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 9/99 | 7/99 | 17/99 |
| OEDEMA PERIPHERALGeneral disorders | 12/99 | 9/99 | 16/99 |
| COUGHRespiratory, thoracic and mediastinal disorders | 8/99 | 6/99 | 15/99 |
| PYREXIAGeneral disorders | 13/99 | 6/99 | 5/99 |
| BACK PAINMusculoskeletal and connective tissue disorders | 12/99 | 7/99 | 8/99 |
| BRONCHITISInfections and infestations | 7/99 | 8/99 | 11/99 |
| Age, Customized(Participants) | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo | Total |
|---|---|---|---|---|
| 16 - 29 years | 55 | 52 | 46 | 153 |
| 30 - 39 years | 28 | 30 | 33 | 91 |
| 40 - 49 years | 10 | 10 | 18 | 38 |
| 50 - 59 years | 5 | 6 | 2 | 13 |
| >= 60 years | 1 | 1 | 1 | 3 |
| Sex: Female, Male(Participants) | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Female | 84 | 86 | 81 | 251 |
| Male | 15 | 13 | 19 | 47 |
| Race(Participants) | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo | Total |
|---|---|---|---|---|
| White | 28 | 45 | 38 | 111 |
| Black/African American | 6 | 3 | 5 | 14 |
| American Indian/Alaska Native | 0 | 1 | 0 | 1 |
| Native Hawaiian/Other Pacific Islander | 1 | 0 | 0 | 1 |
| Other Asian | 60 | 49 | 55 | 164 |
| Other | 4 | 1 | 2 | 7 |
| Weight, Group(participants) | Abatacept 30/10 mg/kg | Abatacept 10/10 mg/kg | Placebo | Total |
|---|---|---|---|---|
| <60 kg | 54 ± 0.68 | 55 ± 0.62 | 45 ± 0.73 | 154 |
| 60 - 100 kg | 42 | 43 | 51 | 136 |
| >100 kg | 3 | 1 | 4 | 8 |
The record gives a start of Jun 2007, a primary completion of Sep 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abatacept · Mycophenolic Acid
Lupus Erythematosus, Systemic →